Literature DB >> 16717122

Cardiac involvement in Fukuyama-type congenital muscular dystrophy.

Toshio Nakanishi1, Masako Sakauchi, Yoshio Kaneda, Hirofumi Tomimatsu, Kayoko Saito, Makoto Nakazawa, Makiko Osawa.   

Abstract

BACKGROUND: Fukuyama-type congenital muscular dystrophy is an autosomal recessive disorder characterized by generalized skeletal muscle weakness and hypotonia from early infancy and by mental retardation. Little is known about cardiac involvement in patients with Fukuyama-type congenital muscular dystrophy. This study evaluated whether cardiac involvement exists in patients with Fukuyama-type congenital muscular dystrophy. METHODS AND
RESULTS: We evaluated left ventricular function using M-mode and Doppler echocardiography in 34 patients with Fukuyama-type congenital muscular dystrophy. The age ranged from 6 months to 30 years (median: 6 years). A total of 64 recordings were analyzed. Left ventricular dimensions and parameters of systolic function measured included left ventricular end-diastolic dimension, left ventricular fractional shortening, left ventricular wall thickness, and the mean velocity of circumferential fiber shortening and end-systolic wall stress relationship. Left ventricular end-diastolic dimension z score >2 was observed in 2 patients (6%). Left ventricular fractional shortening <0.28 and/or reduced mean velocity of circumferential fiber shortening in the mean velocity of circumferential fiber shortening-end-systolic wall stress relationship were observed in 16 patients (47%). A significant correlation between age and left ventricular fractional shortening was observed, and left ventricular fractional shortening decreased with age. Of 12 patients >15 years of age, 10 (83%) showed decreased left ventricular systolic function. Left ventricular fractional shortening was normal in most patients <10 years of age, and it was reduced in most patients >15 years of age. Five patients died of heart failure or respiratory problems, and a histologic examination confirmed the presence of myocardial fibrosis. No patients showed increased left ventricular wall thickness or a conduction abnormality on electrocardiograms.
CONCLUSION: Cardiac involvement exists in patients with Fukuyama-type congenital muscular dystrophy and becomes evident in older children in the second decade. A cardiac evaluation, including echocardiograms and subsequent follow-up, is important, especially in patients >10 years of age.

Entities:  

Mesh:

Year:  2006        PMID: 16717122     DOI: 10.1542/peds.2005-2469

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  11 in total

Review 1.  The congenital muscular dystrophies: recent advances and molecular insights.

Authors:  Jerry R Mendell; Daniel R Boué; Paul T Martin
Journal:  Pediatr Dev Pathol       Date:  2006 Nov-Dec

2.  Novel cardiovascular findings in association with a POMT2 mutation: three siblings with α-dystroglycanopathy.

Authors:  Hugo R Martinez; William J Craigen; Monika Ummat; Adekunle M Adesina; Timothy E Lotze; John L Jefferies
Journal:  Eur J Hum Genet       Date:  2013-09-04       Impact factor: 4.246

3.  Sarcolemma instability during mechanical activity in Largemyd cardiac myocytes with loss of dystroglycan extracellular matrix receptor function.

Authors:  Zhyldyz Kabaeva; Kailyn E Meekhof; Daniel E Michele
Journal:  Hum Mol Genet       Date:  2011-05-30       Impact factor: 6.150

4.  Compound Heterozygous FKTN Variants in a Patient with Dilated Cardiomyopathy Led to an Aberrant α-Dystroglycan Pattern.

Authors:  Anna Gaertner; Lidia Burr; Baerbel Klauke; Andreas Brodehl; Kai Thorsten Laser; Karin Klingel; Jens Tiesmeier; Uwe Schulz; Edzard Zu Knyphausen; Jan Gummert; Hendrik Milting
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

Review 5.  Cardiac complications of congenital disorders of glycosylation (CDG): a systematic review of the literature.

Authors:  D Marques-da-Silva; R Francisco; D Webster; V Dos Reis Ferreira; J Jaeken; T Pulinilkunnil
Journal:  J Inherit Metab Dis       Date:  2017-07-19       Impact factor: 4.982

6.  Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.

Authors:  Paul T Martin; G Diane Shelton; Peter J Dickinson; Beverly K Sturges; Rui Xu; Richard A LeCouteur; Ling T Guo; Robert A Grahn; Harriet P Lo; Kathryn N North; Richard Malik; Eva Engvall; Leslie A Lyons
Journal:  Neuromuscul Disord       Date:  2008-11-05       Impact factor: 4.296

7.  Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy.

Authors:  Yongping Yue; Ibrahim M Binalsheikh; Stacey B Leach; Timothy L Domeier; Dongsheng Duan
Journal:  Expert Opin Orphan Drugs       Date:  2015-12-17       Impact factor: 0.694

Review 8.  Consensus statement on standard of care for congenital muscular dystrophies.

Authors:  Ching H Wang; Carsten G Bonnemann; Anne Rutkowski; Thomas Sejersen; Jonathan Bellini; Vanessa Battista; Julaine M Florence; Ulrike Schara; Pamela M Schuler; Karim Wahbi; Annie Aloysius; Robert O Bash; Christophe Béroud; Enrico Bertini; Kate Bushby; Ronald D Cohn; Anne M Connolly; Nicolas Deconinck; Isabelle Desguerre; Michelle Eagle; Brigitte Estournet-Mathiaud; Ana Ferreiro; Albert Fujak; Nathalie Goemans; Susan T Iannaccone; Patricia Jouinot; Marion Main; Paola Melacini; Wolfgang Mueller-Felber; Francesco Muntoni; Leslie L Nelson; Jes Rahbek; Susana Quijano-Roy; Caroline Sewry; Kari Storhaug; Anita Simonds; Brian Tseng; Jiri Vajsar; Andrea Vianello; Reinhard Zeller
Journal:  J Child Neurol       Date:  2010-11-15       Impact factor: 1.987

9.  Respiratory and cardiac function in congenital muscular dystrophies with alpha dystroglycan deficiency.

Authors:  M Pane; S Messina; G Vasco; A R Foley; L Morandi; E Pegoraro; T Mongini; A D'Amico; F Bianco; M E Lombardo; R Scalise; C Bruno; A Berardinelli; A Pini; I Moroni; M Mora; A Toscano; M Moggio; G Comi; F M Santorelli; E Bertini; F Muntoni; E Mercuri
Journal:  Neuromuscul Disord       Date:  2012-06-22       Impact factor: 4.296

10.  Elimination of fukutin reveals cellular and molecular pathomechanisms in muscular dystrophy-associated heart failure.

Authors:  Yoshihiro Ujihara; Motoi Kanagawa; Satoshi Mohri; Satomi Takatsu; Kazuhiro Kobayashi; Tatsushi Toda; Keiji Naruse; Yuki Katanosaka
Journal:  Nat Commun       Date:  2019-12-17       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.